AstraZeneca and Owkin AI Team Up to Create Agentic AI Agents
AstraZeneca and Owkin have finalized a three-year agreement with each other in hopes to accelerate drug development and strategic decision making. After the success of their first partnership, which produced AI-powered pre scanning tools, this agreements main focus is on developing agentic AI agents using K Pro. These agents will be soon be able to perform complex research tasks that currently require human analysis.